These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 38829615)

  • 1. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review.
    Patel K; Ivanov A; Jocelyn T; Hantel A; Garcia JS; Abel GA
    JAMA Netw Open; 2024 Jun; 7(6):e2414425. PubMed ID: 38829615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy: A Systematic Review.
    Fabian A; Domschikowski J; Letsch A; Schmalz C; Freitag-Wolf S; Dunst J; Krug D
    JAMA Netw Open; 2022 Sep; 5(9):e2231930. PubMed ID: 36136335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
    Addeo A; Weiss GJ; Gyawali B
    JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
    Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
    Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0.
    Moore T; Nees D; Hightower B; Brock L; Kee M; Wise A; Heigle B; Ottwell R; Hartwell M; Vassar M
    Respir Med Res; 2023 Jun; 83():100962. PubMed ID: 36563550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals.
    Khan MS; Khan MS; Ansari ZN; Siddiqi TJ; Khan SU; Riaz IB; Asad ZUA; Mandrola J; Wason J; Warraich HJ; Stone GW; Bhatt DL; Kapadia SR; Kalra A
    JAMA Netw Open; 2020 Apr; 3(4):e203082. PubMed ID: 32301992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
    Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L
    Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.
    Bylicki O; Gan HK; Joly F; Maillet D; You B; Péron J
    Ann Oncol; 2015 Jan; 26(1):231-237. PubMed ID: 25355720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
    Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
    Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation.
    Mercieca-Bebber RL; Perreca A; King M; Macann A; Whale K; Soldati S; Jacobs M; Efficace F
    Eur J Cancer; 2016 Mar; 56():144-161. PubMed ID: 26851406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Missed Opportunity.
    Chadha J; Adashek JJ; Jim H; Kim Y; Semaan A; Chakiryan NH; Safa H; Hajiran A; Sexton W; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
    Clin Genitourin Cancer; 2022 Apr; 20(2):e158-e165. PubMed ID: 34974985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting of patient-reported outcomes in trials on alcohol use disorder: a meta-epidemiological study.
    Douglas A; Garrett E; Staggs J; Williams C; Shepard S; Wise A; Hillman C; Ottwell R; Hartwell M; Vassar M
    BMJ Evid Based Med; 2023 Feb; 28(1):21-29. PubMed ID: 35470132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review.
    Roets E; van der Graaf W; van Riet BHG; Haas RL; Younger E; Sparano F; Wilson R; van der Mierden S; Steeghs N; Efficace F; Husson O
    Crit Rev Oncol Hematol; 2024 May; 197():104345. PubMed ID: 38582227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sickle Cell Disease and Quality of Life: An Evaluation of Reporting of Patient-Reported Outcomes in Randomized Controlled Trials.
    Renner A; Love M; Garrett E; Douglas A; Kee M; Heigle B; Wise A; Ottwell R; Hartwell M; Vassar M
    Hemoglobin; 2022 Sep; 46(5):265-268. PubMed ID: 36268837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review.
    Chakraborty R; Cannella L; Cottone F; Efficace F
    Lancet Haematol; 2020 Dec; 7(12):e892-e901. PubMed ID: 33242446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
    Malone E; Barua R; Meti N; Li X; Fazelzad R; Hansen AR
    Cancer Med; 2021 Aug; 10(15):5031-5040. PubMed ID: 34184416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes (PROs) in randomised controlled trials in diabetes and pregnancy: protocol for a systematic review.
    Newman C; Kgosidialwa O; Dervan L; Bogdanet D; Egan AM; Biesty L; Devane D; O'Shea PM; Dunne F
    BMJ Open; 2021 Nov; 11(11):e052506. PubMed ID: 34728453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.